Decoy Therapeutics Inc. (DCOY)

Decoy Therapeutics Inc. is a preclinical biotechnology company developing peptide conjugate medicines for infectious diseases and cancer. The company was previously known as Salarius Pharmaceuticals and took the Decoy Therapeutics name in January 2026, when its Nasdaq ticker changed to DCOY.

Its core technology is the IMP3ACT platform, which uses computational design and machine learning to create alpha-helical peptides and then engineer and manufacture peptide conjugates that combine those peptides with other molecules. The approach is intended to speed up discovery and allow the company to build a portfolio of candidates aimed at targets that are hard to reach with conventional drugs.

In infectious disease the company has focused on antiviral approaches, while in oncology it is applying the platform to cancer targets. The company has not yet brought products to market.